{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T15:44:44Z","timestamp":1790264684622,"version":"4.1.0"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T00:00:00Z","timestamp":1474502400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T00:00:00Z","timestamp":1474502400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2017,3]]},"DOI":"10.1038\/leu.2016.254","type":"journal-article","created":{"date-parts":[[2016,9,22]],"date-time":"2016-09-22T02:41:58Z","timestamp":1474512118000},"page":"697-704","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":105,"title":["PR1 peptide vaccine induces specific immunity with clinical responses in myeloid malignancies"],"prefix":"10.1038","volume":"31","author":[{"given":"M H","family":"Qazilbash","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Wieder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P F","family":"Thall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"X","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R","family":"Rios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Kanodia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K E","family":"Ruisaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S A","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E H","family":"Estey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Cortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K V","family":"Komanduri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Clise-Dwyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Alatrash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Q","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R E","family":"Champlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J J","family":"Molldrem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,22]]},"reference":[{"key":"BFleu2016254_CR1","doi-asserted-by":"crossref","first-page":"2450","DOI":"10.1182\/blood.V88.7.2450.bloodjournal8872450","volume":"88","author":"J Molldrem","year":"1996","unstructured":"Molldrem J, Dermime S, Parker K, Jiang YZ, Mavroudis D, Hensel N et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood 1996; 88: 2450\u20132457.","journal-title":"Blood"},{"issue":"Suppl 1","key":"BFleu2016254_CR2","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bbmt.2005.10.014","volume":"12","author":"JJ Molldrem","year":"2006","unstructured":"Molldrem JJ . Vaccination for leukemia. Biol Blood Marrow Transplant 2006; 12 (Suppl 1): 13\u201318.","journal-title":"Biol Blood Marrow Transplant"},{"key":"BFleu2016254_CR3","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1182\/blood.V90.7.2529","volume":"90","author":"JJ Molldrem","year":"1997","unstructured":"Molldrem JJ, Clave E, Jiang YZ, Mavroudis D, Raptis A, Hensel N et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood 1997; 90: 2529\u20132534.","journal-title":"Blood"},{"key":"BFleu2016254_CR4","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1038\/79526","volume":"6","author":"JJ Molldrem","year":"2000","unstructured":"Molldrem JJ, Lee PP, Wang C, Felio K, Kantarjian HM, Champlin RE et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat Med 2000; 6: 1018\u20131023.","journal-title":"Nat Med"},{"key":"BFleu2016254_CR5","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1172\/JCI200316398","volume":"111","author":"JJ Molldrem","year":"2003","unstructured":"Molldrem JJ, Lee PP, Kant S, Wieder E, Jiang W, Lu S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J Clin Invest 2003; 111: 639\u2013647.","journal-title":"J Clin Invest"},{"key":"BFleu2016254_CR6","doi-asserted-by":"publisher","first-page":"6541","DOI":"10.1182\/blood-2009-02-202598","volume":"113","author":"U Keilholz","year":"2009","unstructured":"Keilholz U, Letsch A, Busse A, Asemissen AM, Bauer S, Blau IW et al. A clinical and immunologic phase 2 trial of Wilms tumor gene product 1 (WT1) peptide vaccination in patients with AML and MDS. Blood 2009; 113: 6541\u20136548.","journal-title":"Blood"},{"key":"BFleu2016254_CR7","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1182\/blood-2007-08-108241","volume":"111","author":"K Rezvani","year":"2008","unstructured":"Rezvani K, Yong AS, Mielke S, Savani BN, Musse L, Superata J et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood 2008; 111: 236\u2013242.","journal-title":"Blood"},{"key":"BFleu2016254_CR8","doi-asserted-by":"publisher","first-page":"2132","DOI":"10.1182\/blood-2002-01-0163","volume":"100","author":"C Scheibenbogen","year":"2002","unstructured":"Scheibenbogen C, Letsch A, Thiel E, Schmittel A, Mailaender V, Baerwolf S et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood 2002; 100: 2132\u20132137.","journal-title":"Blood"},{"key":"BFleu2016254_CR9","doi-asserted-by":"publisher","first-page":"13885","DOI":"10.1073\/pnas.0405884101","volume":"101","author":"Y Oka","year":"2004","unstructured":"Oka Y, Tsuboi A, Taguchi T, Osaki T, Kyo T, Nakajima H et al. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc Natl Acad Sci USA 2004; 101: 13885\u201313890.","journal-title":"Proc Natl Acad Sci USA"},{"key":"BFleu2016254_CR10","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1182\/blood-2009-10-250993","volume":"116","author":"PG Maslak","year":"2010","unstructured":"Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010; 116: 171\u2013179.","journal-title":"Blood"},{"key":"BFleu2016254_CR11","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1182\/blood-2003-03-0954","volume":"103","author":"K Cathcart","year":"2004","unstructured":"Cathcart K, Pinilla-Ibarz J, Korontsvit T, Schwartz J, Zakhaleva V, Papadopoulos EB et al. A multivalent bcr-abl fusion peptide vaccination trial in patients with chronic myeloid leukemia. Blood 2004; 103: 1037\u20131042.","journal-title":"Blood"},{"key":"BFleu2016254_CR12","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/S0140-6736(05)70931-4","volume":"365","author":"M Bocchia","year":"2005","unstructured":"Bocchia M, Gentili S, Abruzzese E, Fanelli A, Iuliano F, Tabilio A et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet 2005; 365: 657\u2013662.","journal-title":"Lancet"},{"key":"BFleu2016254_CR13","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1038\/leu.2008.7","volume":"22","author":"PG Maslak","year":"2008","unstructured":"Maslak PG, Dao T, Gomez M, Chanel S, Packin J, Korontsvit T et al. A pilot vaccination trial of synthetic analog peptides derived from the BCR-ABL breakpoints in CML patients with minimal disease. Leukemia 2008; 22: 1613\u20131616.","journal-title":"Leukemia"},{"key":"BFleu2016254_CR14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1111\/j.1365-2141.1985.tb04063.x","volume":"61","author":"T Vallespi","year":"1985","unstructured":"Vallespi T, Torrabadella M, Julia A, Irriguible D, Jaen A, Acebedo G et al. Myelodysplastic syndromes: a study of 101 cases according to the FAB classification. Br J Haematol 1985; 61: 83\u201392.","journal-title":"Br J Haematol"},{"key":"BFleu2016254_CR15","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1038\/sj.leu.2401033","volume":"12","author":"J Cortes","year":"1998","unstructured":"Cortes J, Kantarjian H, O'Brien S, Kurzrock R, Keating M, Talpaz M . GM-CSF can improve the cytogenetic response obtained with interferon-alpha therapy in patients with chronic myelogenous leukemia. Leukemia 1998; 12: 860\u2013864.","journal-title":"Leukemia"},{"key":"BFleu2016254_CR16","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1084\/jem.174.1.27","volume":"174","author":"JHF Falkenburg","year":"1991","unstructured":"Falkenburg JHF, Goselink HM, Van der Harst D, Van Luxemburg-Heijs SAP, Kooy-Winkelaar YMC, Faber LM et al. Growth inhibition of clonogenic leukemic precursor cells by minor histocompatibility antigen-specific cytotoxic T lymphocytes. J Exp Med 1991; 174: 27\u201333.","journal-title":"J Exp Med"},{"key":"BFleu2016254_CR17","first-page":"3671","volume":"96","author":"BD Cheson","year":"2000","unstructured":"Cheson BD, Bennett JM, Kantarjian H, Pinto A, Schiffer CA, Nimer SD et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000; 96: 3671\u20133674.","journal-title":"Blood"},{"key":"BFleu2016254_CR18","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14<1563::AID-SIM873>3.0.CO;2-L","volume":"17","author":"PF Thall","year":"1998","unstructured":"Thall PF, Sung HG . Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. Stat Med 1998; 17: 1563\u20131580.","journal-title":"Stat Med"},{"key":"BFleu2016254_CR19","volume-title":"Statistical Methods. 107","author":"GW Snedecor","year":"1980","unstructured":"Snedecor GW, Cochran WG . Statistical Methods. 107. Iowa State University Press: Ames, IA, USA, 1980."},{"key":"BFleu2016254_CR20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1111\/j.2517-6161.1972.tb00899.x","volume":"34","author":"DR Cox","year":"1972","unstructured":"Cox DR . Regression models and life tables (with discussion). J R Stat Soc Ser B 1972; 34: 187\u2013220.","journal-title":"J R Stat Soc Ser B"},{"key":"BFleu2016254_CR21","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3294-8","volume-title":"Modelling Survival Data: Extending the Cox Model","author":"TM Therneau","year":"2000","unstructured":"Therneau TM, Grambsch PM . Modelling Survival Data: Extending the Cox Model. Springer: New York, NY, USA, 2000."},{"key":"BFleu2016254_CR22","doi-asserted-by":"publisher","DOI":"10.1007\/978-1-4757-3121-7","volume-title":"Modern Applied Statistics with S-PLUS","author":"WN Venables","year":"1999","unstructured":"Venables WN, Ripley BD . Modern Applied Statistics with S-PLUS. Springer: New York, NY, USA, 1999."},{"key":"BFleu2016254_CR23","doi-asserted-by":"publisher","first-page":"e11770","DOI":"10.1371\/journal.pone.0011770","volume":"5","author":"S Kanodia","year":"2010","unstructured":"Kanodia S, Wieder E, Lu S, Talpaz M, Alatrash G, Clise-Dwyer K et al. PR1-specific T cells are associated with unmaintained cytogenetic remission of chronic myelogenous leukemia after interferon withdrawal. PLoS One 2010; 5: e11770.","journal-title":"PLoS One"},{"key":"BFleu2016254_CR24","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1097\/00002281-200201000-00004","volume":"14","author":"CO Savage","year":"2002","unstructured":"Savage CO, Harper L, Holland M . New findings in pathogenesis of antineutrophil cytoplasm antibody-associated vasculitis. Curr Opin Rheumatol 2002; 14: 15\u201322.","journal-title":"Curr Opin Rheumatol"},{"key":"BFleu2016254_CR25","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/25374","volume":"396","author":"DC Douek","year":"1998","unstructured":"Douek DC, McFarland RD, Keiser PH, Gage EA, Massey JM, Haynes BF et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 1998; 396: 690\u2013695.","journal-title":"Nature"},{"key":"BFleu2016254_CR26","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1126\/science.290.5489.92","volume":"290","author":"A Lanzavecchia","year":"2000","unstructured":"Lanzavecchia A, Sallusto F . Dynamics of T lymphocyte responses: intermediates, effectors, and memory cells. Science (New York, NY) 2000; 290: 92\u201397.","journal-title":"Science (New York, NY)"},{"key":"BFleu2016254_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.coi.2005.04.010","volume":"17","author":"A Lanzavecchia","year":"2005","unstructured":"Lanzavecchia A, Sallusto F . Understanding the generation and function of memory T cell subsets. Curr Opin Immunol 2005; 17: 326\u2013332.","journal-title":"Curr Opin Immunol"},{"key":"BFleu2016254_CR28","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1038\/nm0898-953","volume":"4","author":"KV Komanduri","year":"1998","unstructured":"Komanduri KV, Viswanathan MN, Wieder ED, Schmidt DK, Bredt BM, Jacobson MA et al. Restoration of cytomegalovirus-specific CD4+ T-lymphocyte responses after ganciclovir and highly active antiretroviral therapy in individuals infected with HIV-1. Nat Med 1998; 4: 953\u2013956.","journal-title":"Nat Med"},{"key":"BFleu2016254_CR29","doi-asserted-by":"publisher","first-page":"1721","DOI":"10.1038\/leu.2008.161","volume":"22","author":"AS Yong","year":"2008","unstructured":"Yong AS, Keyvanfar K, Eniafe R, Savani BN, Rezvani K, Sloand EM et al. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia 2008; 22: 1721\u20131727.","journal-title":"Leukemia"},{"key":"BFleu2016254_CR30","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1182\/blood.V95.5.1781.005k46_1781_1787","volume":"95","author":"J Pinilla-Ibarz","year":"2000","unstructured":"Pinilla-Ibarz J, Cathcart K, Korontsvit T, Soignet S, Bocchia M, Caggiano J et al. Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses. Blood 2000; 95: 1781\u20131787.","journal-title":"Blood"},{"key":"BFleu2016254_CR31","doi-asserted-by":"publisher","first-page":"2287","DOI":"10.1038\/sj.leu.2404858","volume":"21","author":"JM Rojas","year":"2007","unstructured":"Rojas JM, Knight K, Wang L, Clark RE . Clinical evaluation of BCR-ABL peptide immunisation in chronic myeloid leukaemia: results of the EPIC study. Leukemia 2007; 21: 2287\u20132295.","journal-title":"Leukemia"},{"key":"BFleu2016254_CR32","doi-asserted-by":"publisher","first-page":"2238","DOI":"10.1182\/blood-2008-04-151969","volume":"113","author":"JJ Melenhorst","year":"2009","unstructured":"Melenhorst JJ, Scheinberg P, Chattopadhyay PK, Gostick E, Ladell K, Roederer M et al. High avidity myeloid leukemia-associated antigen-specific CD8+ T cells preferentially reside in the bone marrow. Blood 2009; 113: 2238\u20132244.","journal-title":"Blood"},{"issue":"4","key":"BFleu2016254_CR33","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1053\/j.seminhematol.2010.06.006","volume":"47","author":"Bing Z. Carter","year":"2010","unstructured":"Carter BZ, Mak DH, Cortes J, Andreeff M . The elusive chronic myeloid leukemia stem cell: does it matter and how do we eliminate it? Semin Hematol Oct 47: 362\u2013370.","journal-title":"Seminars in Hematology"},{"key":"BFleu2016254_CR34","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.cell.2015.03.030","volume":"161","author":"P Sharma","year":"2015","unstructured":"Sharma P, Allison JP . Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 2015; 161: 205\u2013214.","journal-title":"Cell"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/leu2016254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016254","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/leu2016254.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,19]],"date-time":"2024-06-19T10:16:51Z","timestamp":1718792211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/leu2016254"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,22]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2017,3]]}},"alternative-id":["BFleu2016254"],"URL":"https:\/\/doi.org\/10.1038\/leu.2016.254","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,22]]},"assertion":[{"value":"16 April 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2016","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2016","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}